|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| Current assets | |||||||||
| Cash | |||||||||
| Prepaid income tax | |||||||||
| Prepaid franchise taxes | |||||||||
| Prepaid expenses | |||||||||
| Total Current Assets | |||||||||
| Deferred offering costs | |||||||||
| Long-term prepaid insurance | |||||||||
| Investments held in Trust Account | |||||||||
| TOTAL ASSETS | |||||||||
| Current liabilities | |||||||||
| Accounts payable and accrued expenses | |||||||||
| Accrued offering costs | |||||||||
| Income tax payable | |||||||||
| Excise tax payable attributable to redemption of common stock | |||||||||
| Promissory notes – related party | |||||||||
| Total Current Liabilities | |||||||||
| Deferred underwriting fee | |||||||||
| Deferred underwriting fee | |||||||||
| TOTAL LIABILITIES | |||||||||
| Common Stock Subject to Possible Redemption (Notes 2 and 7) | |||||||||
| Common stock subject to possible redemption, 1,030,715 and 6,900,000 shares issued and outstanding at redemption value of $10.76 and $10.35 per share as of September 30, 2026 and December 31, 2025, respectively | |||||||||
| STOCKHOLDERS’ DEFICIT | |||||||||
| Common stock, $0.0001 par value; 40,000,000 shares authorized; 2,685,750 shares issued and outstanding (excluding 1,030,715 and 6,900,000 shares subject to possible redemption) at September 30, 2026 and December 31, 2025, respectively | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated deficit | |||||||||
| Total Stockholders’ Deficit | |||||||||
| TOTAL LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ DEFICIT |
Loading...